




Agenda



- Background
- Research findings
- Who's to blame?
- What could pharmaceutical manufacturers do?
- Conclusions








Background



- Health supply chain projects in Tanzania, Zambia
 - SMS for Life
 - ACT stock reporting by text message
 - eZICS
 - The "stockout eliminator"
- Proved it's theoretically possible to get medicines to populations in sub-Saharan Africa
- So what's inhibiting adherence?



Research findings: example inhibitors





- "I lacked water for taking medicine"
- "We are poor, we can't afford most of the requirements. Sometimes we have single meal a day"
- "The side effects were a bit too much for me"
- "If you don't have money you can just take some local medicine"
- "...too many [malaria] tablets. So I took my pawpaws that I heard about on the radio"
- "I feared for stigma... you are viewed in a different manner by community members"
- "I hate the bitterness and largeness of the tabs"
- "I stop when I feel better... I keep it just in case I get a recurrence of same symptom"

Research findings: ORS inhibitors








- "One litre is too much so I take a spoon of ORS and put it in a glass of water"
- "My child is not able to drink the full litre in 24 hours so I have to throw away the left over. It's such a waste"
- "I don't know what is one litre"
- "I don't have clean water at hand"
- "I just heat the water, it's too costly to boil it for 15 minutes"
- "The product is disgusting and sometimes my child vomits it"

What is adherence? And who's to blame?





What can be done?





- Improved value propositions may include:
 - Water with medicine
 - Food with medicine
 - Shorter regimens
 - Relaxed scheduling constraints
 - Clearer instructions
 - Reduced tablet size
 - Improved medicine taste
 - Enhanced packaging appeal
 - Clarification of instructions
 - Reminders set in app based on barcode
- How many of those would we welcome as reverse innovations?

ORS results to date









Opinions of 630 caregivers in 3 countries











New Indian ORS sachet



New Ugandan ORS sachet



New Nigerian co-pack



Smaller sachets, orange-flavoured, with brighter and more attractive packs

Conclusions



- Pharmaceutical manufacturers "...are going to be paid on patient outcomes"
 - Joseph Jimenez, CEO of Novartis, 2013
- Which means improving adherence
- I am convinced that making medicines easier to consume can be a significant contributor
- Doing that for sub-Saharan Africa could benefit all of us



Shaping the Future





Email: p.m.ward@warwick.ac.uk Twitter: @Peter_Ward

Coventry CV4 7AL UK Tel: +44 (0)1926 854115 Web: www.bit.ly/iipsi







Peter Ward

Warwick Manufacturing Group
'Making Medicine Easier to Take in Sub-Saharan
Africa'